Chunping Qiu

No. 107 Wenhua Road
Jinan, 250012, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Progress of immunotherapies in gestational trophoblastic neoplasms.

Progress of immunotherapies in gestational trophoblastic neoplasms.

Journal: Journal of cancer research and clinical oncology

Published: May 22, 2023

LncRNA HOXB-AS3 binding to PTBP1 protein regulates lipid metabolism by targeting SREBP1 in endometrioid carcinoma.

LncRNA HOXB-AS3 binding to PTBP1 protein regulates lipid metabolism by targeting SREBP1 in endometrioid carcinoma.

Journal: Life sciences

Published: November 18, 2022

Verteporfin reverses progestin resistance through YAP/TAZ-PI3K-Akt pathway in endometrial carcinoma.

Verteporfin reverses progestin resistance through YAP/TAZ-PI3K-Akt pathway in endometrial carcinoma.

Journal: Cell death discovery

Published: November 18, 2022

Novel insights into tumorigenesis and prognosis of endometrial cancer through systematic investigation and validation on mitophagy-related signature.

Novel insights into tumorigenesis and prognosis of endometrial cancer through systematic investigation and validation on mitophagy-related signature.

Journal: Human cell

Published: November 07, 2022

ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by targeting MGLL.

ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by targeting MGLL.

Journal: Cell death & disease

Published: June 10, 2022

MEX3A promotes the malignant progression of ovarian cancer by regulating intron retention in TIMELESS.

MEX3A promotes the malignant progression of ovarian cancer by regulating intron retention in TIMELESS.

Journal: Cell death & disease

Published: December 27, 2021

HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer.

HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer.

Journal: International journal of biological sciences

Published: August 01, 2021

Splicing Factor DDX23, Transcriptionally Activated by E2F1, Promotes Ovarian Cancer Progression by Regulating FOXM1.

Splicing Factor DDX23, Transcriptionally Activated by E2F1, Promotes Ovarian Cancer Progression by Regulating FOXM1.

Journal: Frontiers in oncology

Published: July 29, 2021

MiR-501 promotes tumor proliferation and metastasis by targeting HOXD10 in endometrial cancer.

MiR-501 promotes tumor proliferation and metastasis by targeting HOXD10 in endometrial cancer.

Journal: Cellular & molecular biology letters

Published: February 02, 2021

CNR1 may reverse progesterone-resistance of endometrial cancer through the ERK pathway.

CNR1 may reverse progesterone-resistance of endometrial cancer through the ERK pathway.

Journal: Biochemical and biophysical research communications

Published: January 10, 2021

Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma.

Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma.

Journal: Cell death & disease

Published: November 30, 2020

IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer.

IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer.

Journal: Oncology letters

Published: November 25, 2019

Showing 1-12 of 30

Last Updated: 09/26/2026